FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026?

FHLC offers a much lower expense ratio at 0.08% versus 0.38% for IYH, while also delivering a slightly higher dividend yield of 1.40% versus 1.28%. IYH is more concentrated with 101 holdings compared with FHLC's 338, but both funds show similar risk, with five-year max drawdowns of about 17.7%-17.9% and comparable beta. The article favors FHLC for broader healthcare exposure and lower costs, though the content is mainly comparative ETF commentary rather than a price-moving catalyst.

Analysis

The real winner here is not simply the cheaper fund; it is the broader healthcare beta embedded in smaller-cap biotech and med-tech that FHLC captures and IYH largely leaves behind. If the sector keeps rewarding dispersion rather than just mega-cap defensives, FHLC should get a structural return advantage because the fee gap and incremental exposure to underowned names compound together. By contrast, IYH is effectively a concentrated proxy for a handful of large-cap pharma cash machines, so its upside is more dependent on a narrow set of clinical and policy outcomes.

The second-order effect is positioning. A lower-cost, higher-yield broad healthcare vehicle can become the default parking spot for defensive allocations, which may compress the valuation premium of the mega-cap weights over time while gradually widening the relative performance of mid-cap and sub-sector names inside FHLC. That creates a subtle headwind for IYH: when flows chase “defensive healthcare” broadly, concentration becomes a liability because the fund is already overexposed to the same few names investors can own directly.

The main risk is that leadership stays extremely narrow and the mega-caps continue to outperform on earnings revisions, pricing power, and capital returns. In that regime, IYH’s concentrated exposure can beat FHLC for months, even if FHLC wins over years on fees and diversification. The catalyst to watch is whether market breadth inside healthcare improves; if it does, FHLC should outperform quickly, but if the sector becomes a pure LLY/JNJ/ABBV trade, IYH’s construction turns into a feature rather than a bug.

The contrarian angle is that investors may be overpaying for concentration at exactly the wrong point in the cycle. With rates still a key valuation input, the market tends to reward visible cash flows, but in healthcare that often means the consensus crowding into the same three names, which increases single-stock risk without necessarily improving total return. FHLC is the cleaner expression for long-duration sector exposure; IYH is a tactical trade on continued mega-cap leadership, not a superior strategic hold.

Key Decisions for Investors

• Rotate core healthcare exposure from IYH to FHLC over the next 1-2 weeks; the expected edge is modest in any single quarter, but the fee and diversification differential should create a 50-100 bps annualized advantage before stock selection effects.
• If retaining IYH, pair it against FHLC as a relative-value trade: long FHLC / short IYH for 3-6 months with a stop if LLY-led concentration keeps outperforming by more than ~5% on a rolling 1-quarter basis.
• Use FHLC as the default defensive sleeve for equity portfolios rather than direct mega-cap baskets; it is the better risk budget allocator if you want healthcare exposure without single-name concentration risk.
• For traders wanting catalyst-driven upside, keep IYH only as a tactical long into earnings or regulatory catalysts for LLY/JNJ/ABBV; otherwise the concentration premium is hard to justify.
• Avoid adding both funds simultaneously in the same portfolio bucket; they overlap heavily, so owning both dilutes conviction without meaningfully improving diversification.